Prostate SPORE Project 4
A Randomized Phase II Clinical Trial to Determine the Safety, Tolerability and Efficacy of an Allogeneic Whole Cell Vaccine Administered With or Without Autologous Myeloid Dendritic Cells to Patients Suffering From Androgen Independent Prostate Carcinoma
Principal Investigator: Stanimir Vuk-Pavlovic, Ph.D.
The specific aims of this study are:
To execute the clinical trial, we are collaborating with the vaccine manufacturer Onyvax Ltd, Tooting, England. The proposed clinical trial is technically, medically and ethically feasible. It is based on technologies and clinical-grade products that have been approved and tested for human use or are amenable to rapid approval. These cellular products are minimally toxic, particularly in comparison to systemic cytotoxic agents. Our combined resources, expertise, past experience and operating infrastructure provide a unique environment to continue pushing the limits of immunotherapy of prostate cancer.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.